"Mebufotenin Nasal Spray for Treatment-Resistant Depression: One Dose, Eight Weeks of Relief"

A drug synthesized from a compound found in toad venom, sprayed once into a single nostril and gone from the body within hours, has now passed one of the most rigorous tests psychiatry can give it. The results, published this month in JAMA, are the reason I keep returning to a simple idea: in mental health care, the scarcest resource is not a molecule. It is time.

The drug is mebufotenin, better known as 5-MeO-DMT, in an intranasal formulation called BPL-003 developed by Beckley Psytech and atai Life Sciences. The Phase 2b trial behind the JAMA paper enrolled 196 people with treatment-resistant depression across 38 sites in Australia, Europe and the United States; 193 were included in the primary analysis. Every participant had moderate to severe major depression that had not responded to between two and five antidepressant trials during the current episode. Each received a single dose of the nasal spray, 0.3 mg, 8 mg or 12 mg, delivered by a trained clinician with psychological support and more than four hours of observation.

At day 29, the trial's primary endpoint, the 12 mg group had improved by 11.1 points on the Montgomery-Asberg Depression Rating Scale, against 5.5 points for the 0.3 mg comparator group, a difference of 5.3 points that was statistically significant. The 8 mg group improved by 12.1 points. The benefits appeared within a day of dosing and were generally maintained through eight weeks of follow-up. Most patients were ready to leave the clinic about two hours after the spray.

That two-hour figure is the one I cannot stop thinking about. Esketamine, the approved rapid-acting option, requires in-clinic monitoring and a long observation window; psilocybin sessions occupy most of a day with trained guides present throughout. Mebufotenin's psychedelic effects peak and fade within about an hour, and this trial suggests the whole appointment could fit into an ordinary clinic morning. If psychiatry has a throughput problem, and it plainly does, with millions of people waiting for care that does not arrive, then a shorter session is not a convenience. It is capacity.

The honest caveats matter as much as the headline. The comparator was a low dose of the same drug, not an inert placebo, and blinding is notoriously difficult when the treatment produces an unmistakable psychedelic experience, so some of the gap may reflect expectancy. Eight weeks is not a cure: treatment-resistant depression is chronic and relapsing, and the trial does not yet show how often retreatment is needed or how durable the benefit is beyond its window. The open-label extension, in which patients could receive a second dose, reported a 63 percent response rate and 48 percent remission at day 57, but that phase was not blinded. And the drug itself remains a Schedule I substance in the United States, which means every step toward the clinic runs through regulatory terrain that has slowed psychedelic medicine before.

What happens next is already mapped out. BPL-003 holds FDA Breakthrough Therapy designation, the FDA endorsed moving to Phase 3 after an end-of-Phase-2 meeting, and the company plans two pivotal trials, ReConnection-1 and ReConnection-2, with topline results guided for early 2029. The Phase 2b paper is the foundation; the Phase 3 program is the test of whether a one-hour psychedelic experience and a two-hour clinic visit can scale into something ordinary. That is a question worth tracking, because the answer will decide whether this becomes a treatment patients can actually get, or another promising result that stays in journals.